Hypertension, antihypertensive therapy and renal-cell cancer: A meta-analysis

Current Drug Safety

Volumn 2, Issue 2, 2007, Pages 125-133

  Corrao, Giovanni ^a   Scotti, Lorenza ^a   Bagnardi, Vincenzo ^a   Sega, Roberto ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Antihypertensive medicaments; Hypertension; Meta analysis; Renal cell cancer

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

BODY MASS; CANCER RISK; CAUSAL ATTRIBUTION; CHEMICAL CARCINOGENESIS; CONFIDENCE INTERVAL; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; EVIDENCE BASED MEDICINE; HIGH RISK POPULATION; HUMAN; HYPERTENSION; KIDNEY CANCER; MEDLINE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SMOKING; STATISTICAL SIGNIFICANCE; TREATMENT DURATION;

ANTIHYPERTENSIVE AGENTS; CARCINOMA, RENAL CELL; DIURETICS; FEMALE; HUMANS; HYPERTENSION; KIDNEY NEOPLASMS; MALE; ODDS RATIO; RISK FACTORS; SEX FACTORS;

EID: 34249284139     PISSN: 15748863     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488607780598296     Document Type: Review

References (54)

1. Vogelzang NJ, Stadler WM. Kidney cancer. Lancet 1998; 352: 1691-6.
2. Chow WH, Devesa SS, Warren JL, Fraumeni JF Jr. Rising incidence of renal cell cancer in the United States. JAMA 1999; 281: 1628-31.
3. Dhote R, Thiounn N, Debre B, Vidal-Trecan G. Risk factors for adult renal cell carcinoma. Urol Clin North Am 2004; 31: 237-47.
4. Grossman E, Messerli FH, Boyko V, Goldbourt U. Is there an association between hypertension and cancer mortality? Am J Med 2002; 112: 479-86.
5. Messerli FH. Risk factors for renal cell carcinoma: hypertension or diuretics? Kidney Int 2005; 67: 774-5.
6. Grossman E, Messerli FH, Goldbourt U. Antihypertensive therapy and the risk of malignancies. Eur Heart J 2001; 22: 1343-52.
7. Grossman E, Messerli FH, Goldbourt U. Does diuretic therapy increase the risk of renal cell carcinoma? Am J Cardiol 1999; 83: 1090-3.
8. Schmieder RE, Delles C, Messerli FH. Diuretic therapy and the risk for renal cell carcinoma. J Nephrol 2000; 13: 343-6.
9. Lee IM, Hennekens CH. Diuretics and renal cell carcinoma (editorial). Am J Cardiol 1999; 83: 1094.
10. Grossman E, Messerli FH. Diuretics and renal cell carcinoma. What is the risk/benefit ratio? Kidney Int 1999; 56: 1603-4.
11. Messerli FH. Diuretic therapy and renal cell carcinoma - another controversy? Eur Heart J 1999; 20: 1441-2.
12. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.
13. Greenland S. Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 1987; 9: 1-30.
14. Egger M, Smith DG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-34.
15. Sterne JAC, Bradburn MJ, Egger M. Meta-analysis in Stara. In: Systematic Reviews in Health Care. Meta-analysis in context. Egger M, Smith GD, Altman DG (eds). BMJ Publishing Group; London, 2003: 347-69.
16. Muscat JE, Hoffmann D, Wynder EL. The epidemiology of renal cell carcinoma. A second look. Cancer 1995; 75: 2552-7.
17. Schlehofer B, Pommer W, Mellemgaard A, et al. International renal-cell-cancer study. VI. the role of medical and family history. Int J Cancer 1996; 66: 723-6.
18. Chow WH, Gridley G, Fraumeni JF Jr, Jarvholm B. Obesity, hypertension, and the risk of kidney cancer in men. N Engl J Med 2000; 343: 1305-11.
19. Grove JS, Nomura A, Severson RK, Stemmermann GN. The association of blood pressure with cancer incidence in a prospective study. Am J Epidemiol 1991; 134: 942-7.
20. Coughlin SS, Neaton JD, Randall B, Sengupta A. Predictors of mortality from kidney cancer in 332,547 men screened for the Multiple Risk Factor Intervention Trial. Cancer 1997; 79: 2171-7.
21. Choi MY, Jee SH, Sull JW, Nam CM. The effect of hypertension on the risk for kidney cancer in Korean men. Kidney Int 2005; 67: 647-52.
22. Liaw KL, Linet MS, McLaughlin JK, et al. Possible relation between hypertension and cancers of the renal pelvis and ureter. Int J Cancer 1997; 70: 265-8.
23. Yu MC, Mack TM, Hanisch R, Cicioni C, Henderson BE. Cigarette smoking, obesity, diuretic use, and coffee consumption as risk factors for renal cell carcinoma. J Natl Cancer Inst 1986; 77: 351-6.
24. Fraser GE, Phillips RL, Beeson WL. Hypertension, antihypertensive medication and risk of renal carcinoma in California Seventh-Day Adventists. Int J Epidemiol 1990; 19: 832-8.
25. McCredie M, Stewart JH. Risk factors for kidney cancer in New South Wales, Australia. II. Urologic disease, hypertension, obesity, and hormonal factors. Cancer Causes Control 1992; 3: 323-31.
26. Finkle WD, McLaughlin JK, Rasgon SA, Yeoh HH, Low JE. Increased risk of renal cell cancer among women using diuretics in the United States. Cancer Causes Control 1993; 4: 555-8.
27. Kreiger N, Marrett LD, Dodds L, Hilditch S, Darlington GA. Risk factors for renal cell carcinoma: results of a population-based case-control study. Cancer Causes Control 1993; 4: 101-10.
28. Mellemgaard A, Moller H, Holsen JK. Diuretics may increase risk of renal cell carcinoma. Cancer Causes Control. 1992; 3: 309-12.
29. Hiatt RA, Tolan K, Quesenberry CP Jr. Renal cell carcinoma and thiazide use: a historical, case-control study (California, USA). Cancer Causes Control 1994; 5: 319-25.
30. Mellemgaard A, Niwa S, Mehl ES, Engholm G, McLaughlin JK, Olsen JH. Risk factors for renal cell carcinoma in Denmark: role of medication and medical history. Int J Epidemiol 1994; 23: 923-30.
31. Weinmann S, Glass AG, Weiss NS, Psaty BM, Siscovick DS, White E. Use of diuretics and other antihypertensive medications in relation to the risk of renal cell cancer. Am J Epidemiol 1994; 140: 792-804.
32. Chow WH, McLaughlin JK, Mandel JS, Wacholder S, Niwa S, Fraumeni JF Jr. Risk of renal cell cancer in relation to diuretics, antihypertensive drugs, and hypertension. Cancer Epidemiol Biomarkers Prev 1995; 4: 327-31.
33. McLaughlin JK, Chow WH, Mandel JS, et al. International renal-cell cancer study. VIII. Role of diuretics, other anti-hypertensive medications and hypertension. Int J Cancer 1995; 63: 216-21.
34. Heath CW Jr, Lally CA, Calle EE, McLaughlin JK, Thun MJ. Hypertension, diuretics, and antihypertensive medications as possible risk factors for renal cell cancer. Am J Epidemiol 1997; 145: 607-13.
35. Prineas RJ, Folsom AR, Zhang ZM, Sellers TA, Potter J. Nutrition and other risk factors for renal cell carcinoma in postmenopausal women. Epidemiology 1997; 8: 31-6.
36. Yuan JM, Castelao JE, Gago-Dominguez M, Ross RK, Yu MC. Hypertension, obesity and their medications in relation to renal cell carcinoma. Br J Cancer 1998; 77: 1508-13.
37. Shapiro JA, Williams MA, Weiss NS, Stergachis A, LaCroix AZ, Barlow WE. Hypertension, antihypertensive medication use, and risk of renal cell carcinoma. Am J Epidemiol 1999; 149: 521-30.
38. Flaherty KT, Fuchs CS, Colditz GA, et al. A prospective study of body mass index, hypertension, and smoking and the risk of renal cell carcinoma (United States). Cancer Causes Control 2005; 16: 1099-106.
39. Fryzek JP, Poulsen AH, Johnsen SP, McLaughlin JK, Sorensen HT, Friis S. A cohort study of antihypertensive treatments and risk of renal cell cancer. Br J Cancer 2005; 92: 1302-6.
40. Schouten LJ, van Dijk BA, Oosterwijk E, et al. Hypertension, antihypertensives and mutations in the Von Hippel-Lindau gene in renal cell carcinoma: results from the Netherlands Cohort Study. J Hypertens 2005; 23: 1997-2004.
41. Meyer P. Increased intracellular calcium: from hypertension to cancer. J Hypertens Suppl 1987; 5(suppl 4): S3-S4.
42. Hamet P. Cancer and hypertension. An unresolved issue. Hypertension 1996; 28: 321-4.
43. Gago-Dominguez M, Castelao JE, Yuan JM, Ross RK, Yu MC. Lipid peroxidation: a novel and unifying concept of the etiology of renal cell carcinoma (United States). Cancer causes Control 2002; 13: 287-93.
44. Ross R. The pathogenesis of atherosclerosis. A perspective for 1990s. Nature 1993; 362: 801-9.
45. Hughes AD, Clunn GF, Refson J, Demoliou-Mason C. Platelet-derived growth factor [PDGF]. Actions and mechanisms in vascular smooth muscle. Gen Pharmacol 1996; 27: 1079-89.
46. Abedi H, Zachary I. Signaling mechanisms in the regulation of vascular cell migration. Cardiovasc Res 1995; 30: 544-56.
47. Gold B, Mirvish SS. N-Nitroso derivates of hydrochlorothiazide, peridazole, and tolbudamide. Toxicol Appl Pharmacol 1977; 40: 131-6.
48. Loffing J, Loffing-Cueni D, Hegyi I, Kaplan MR, Hebert SC, Le Hir M, Kaissling B. Thiazide treatment of rats provokes apoptosis in distal tubule cells. Kidney Int 1996; 50: 1180-90.
49. Verlander JW, Tran TM, Zhang L, Kaplan MR, Hebert SC. Estradiol enhances thiazide-sensitive NaCl cotransporter density in the apical plasma membrane of the distal convoluted tubule in ovariectomized rats. J Clin Invest 1998; 101: 1661-9.
50. NIH Technical Report 356. Toxicology and carcinogenesis ctudies of furosemide (CAS No. 54-31-9) in F344/N rats and B6C3F1 mice (feed studies). Available at: http://ntp.niehs.nih.gov/ index.cfm?objectid=07089914-FDE4-C583-1F13CC110E963972.
51. NIH Technical Report 357. Toxicology and carcinogenesis studies of hydrochlorothiazide (CAS No. 58-93-5) in F344/N rats and B6C3F1 mice (feed studies). Available at: http://ntp.niehs.nih.gov/ index.cfm?objectid-07089EC1-A4F7-29B4-65E5CE11CC2A7E3A.
52. NIH Technical Report 420. Toxicology and carcinogenesis studies of triamterene (CAS No. 396-01-0) in F344/N rats and B6C3F1 mice (feed studies). Available at: http://ntp.niehs.nih.gov/ index.cfm?objectid=0709B5A0-F751-3732-811DCCAC4C222871.
53. Raynor WJ, Shekelle RB, Rossof AH, Maliza C, Paul O. Blood pressure and 17-year cancer mortality in the Western Electric Health Study. Am J Epidemiol 1981; 113: 371-7.
54. Kurt TL. Renal cell cancer in hypertensive patients more likely related to lead exposure than to antihypertensive medication [letter]. Am J Epidemiol 1995; 142: 1123.